Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Analyze Emerging Opportunities in R&D and Business Development in Hematological Cancers.


DUBLIN Dublin, city, Republic of Ireland
Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River.
, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48301) has announced the addition of Analytical analytical, analytic

pertaining to or emanating from analysis.


analytical control
control of confounding by analysis of the results of a trial or test.
 Tool - Hematological hematological, hematologic

pertaining to or emanating from blood cells.


hematological tests
total and differential white cell counts, hematocrit estimation, erythrocyte count.
 Cancers to their offering.

"Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed an·a·lyze  
tr.v. an·a·lyzed, an·a·lyz·ing, an·a·lyz·es
1. To examine methodically by separating into parts and studying their interrelations.

2. Chemistry To make a chemical analysis of.

3.
 to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated val·i·date  
tr.v. val·i·dat·ed, val·i·dat·ing, val·i·dates
1. To declare or make legally valid.

2. To mark with an indication of official sanction.

3.
 and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers - Hematological Cancers - A Therapeutic & Competitive Insight and Hematological Cancers - Drug Pipeline Update 2006.

The Package Includes:

* A progress analysis on current and emerging drugs

* Information on most companies active in R&D

* Information on key industry related projects

* Data from most important clinical trials

* Information on early developmental stage projects

* Possibility of performing advanced searches suited to your individual needs

This Tool will Assist You in:

* Tracking cutting edge companies, therapies and new technologies

* Rapid identification of partners & competitors

* Laying down a comprehensive framework for further analysis of the field

* Producing presentations surrounding sur·round  
tr.v. sur·round·ed, sur·round·ing, sur·rounds
1. To extend on all sides of simultaneously; encircle.

2. To enclose or confine on all sides so as to bar escape or outside communication.

n.
 the development of leukemia leukemia (lkē`mēə), cancerous disorder of the blood-forming tissues (bone marrow, lymphatics, liver, spleen) characterized by excessive production of immature or mature  therapeutics therapeutics

Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry.
 

* Identifying emerging products & key areas of pharmaceutical R&D

This CD-ROM CD-ROM: see compact disc.
CD-ROM
 in full compact disc read-only memory

Type of computer storage medium that is read optically (e.g., by a laser).
 search-able database reflects the most recent advances in the field of hematological cancer drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with this CD-ROM search-able databases is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, this CD-ROM search-able databases give better overview and specific search capabilities.

For more information visit http://www.researchandmarkets.com/reports/c48301
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 12, 2007
Words:413
Previous Article:Data and Insight from Many Leading Retail Market Analysts and Consumer Behavior Specialists Throughout the United States - Consumer Behavior 2007.
Next Article:Research and Markets: 2006 Company Profile on Spar (UK) Elaborates on the Company's Business Structure and Operations, Products and Services.
Topics:



Related Articles
MethylGene Reports Interim Clinical Results for MGCD0103.
New Survival Data on Evoltra(TM) (Clofarabine) in Elderly AML Reported at European Hematology Association Congress.
View Detailed Information on Most Oncology Companies Active in Antibody R&D.
An Analytical Tool That Will Help You in Identifying Emerging Cancer Immunotherapy Products & Key Areas of Pharmaceutical R&D.
Number of Cancer Vaccine Players has Decreased through Operational Re-Prioritizations, M&As and Fall Outs.
Changes in immunological and hematological parameters of female residents exposed to volatile organic compounds in the city of Kaohsiung, Taiwan.
Cyclacel Submits IND of CYC116 an Aurora Kinase and VEGRF2 Inhibitor to Treat Cancer.
ZIOPHARM Initiates ZIO-101 Phase II Study in Hematological Cancers.
Onconova Therapeutics Announces Presentation of Clinical and Non-Clinical Results for Its Lead Compound ON 01910.Na at American Association of Cancer...
Cyclacel Reports Phase I Sapacitabine Data in Patients with Advanced Leukemias and Myelodysplastic Syndromes at 2007 ASCO Annual Meeting.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles